Astrazeneca plc ADR (NASDAQ:AZN) finished Friday with an addition of $0.3 to close at $67.72, an upside of 0.44 percent. An average of 4,087,080 shares of common stock have been traded in the last five days. There was a fall of -$0.11 in the past week, and it reached a new high 33 times over the past 12 months. The last 20 days have seen an average of 4,361,725 shares traded, while the 50-day average volume stands at 4,533,552.
AZN stock has decreased by -1.66% in the last month. The company shares reached their 1-month lowest point of $65.71 on 09/11/23. With the stock rallying to its 52-week high on 04/25/23, shares of the company touched a low of $53.52 and a high of $76.56 in 52 weeks. It has reached a new high 12 times so far this year and lost -0.12% or -$0.08 in price. In spite of this, the price is down -11.55% from the 52-week high.
Valuation Metrics
Astrazeneca plc ADR (AZN) has a trailing price-to-earnings (P/E) ratio of 34.26. The stock’s beta is 0.51. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.72, the price-to-book (PB) ratio at 5.61, and the price-to-cash flow ratio at 22.75.
The company has a payout ratio of 133.71%. The company’s most recent quarterly dividend payment was $0.4650 a share, representing a down of -52.79% from $0.9850 last year. Its latest decrease dividend $0.52 reported on Friday July 28 2023.
Financial Health
The quick ratio of Astrazeneca plc ADR for the three months ended June 29 was 0.67, and the current ratio was 0.87, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.67 and a total debt to equity ratio of 0.80 for the quarter ending June 29. Its gross profit as reported stood at $31.96 billion compared to revenue of $44.35 billion.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $3.29 billion in the quarter, while revenues were grew 96.59%. The analyst consensus anticipated Astrazeneca plc ADR’s latest quarter earnings to come in at $0.95 per share, but it turned out to be $1.08, a 13.70% surprise. For the quarter, EBITDA amounted to $3.73 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Astrazeneca plc ADR (AZN) price momentum. RSI 9-day as of the close on 29 September was 49.26%, suggesting the stock is Neutral, with historical volatility in this time frame at 17.85%.
As of today, AZN’s price is $68.05 -0.16% or -$0.11 from its 5-day moving average. AZN is currently trading -0.15% lower than its 20-day SMA and -10.10% lower than its 100-day SMA. However, the stock’s current price level is -1.23% below the SMA50 and -2.25% below the SMA200.
The stochastic %K and %D were 55.60% and 63.83%, respectively, and the average true range (ATR) was 1.27. With the 14-day stochastic at 55.47% and the average true range at 1.23, the RSI (14) stands at 48.54%. The stock has reached -0.05 on the 9-day MACD Oscillator while the 14-day reading was at 0.11.
Analyst Ratings
Jefferies upgraded Astrazeneca plc ADR (NASDAQ: AZN) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold. The consensus rating for Astrazeneca plc ADR (AZN) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AZN, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 25 others rate it as a “buy”.
What is AZN’s price target for the next 12 months?
Analysts predict a range of price targets between $63.00 and $106.75, with a median target of $81.89. Taking a look at these predictions, the average price target given by analysts for Astrazeneca plc ADR (AZN) stock is $83.68.
